Back to Search
Start Over
Characteristics of clinical trials of new oncology drugs approved in China.
- Source :
- Cancer (0008543X); Mar2024, Vol. 130 Issue 5, p671-682, 12p
- Publication Year :
- 2024
-
Abstract
- Background: Since reforms were introduced to incentivize drug innovation in 2015, the Chinese pharmaceutical market has experienced unprecedented prosperity, with more new drugs than ever before, especially anticancer treatments. In 2021, Chinese regulatory agencies issued the new guideline for clinical research and development of antitumor drugs, triggering a series of responses on the drug market. Limited research has outlined the nature of the original new drugs in China to understand the dynamic response of the market. Methods: The objective of this article was to map the clinical development of approved new oncology drugs in China from 2015 to 2021 and differed from previous studies by focusing on original new drugs, using the United States as a benchmark, and elaborating the endogenous features of clinical trials. Results: Clinical trials conducted in China have risen to a level similar to that of the United States in many aspects of trial design, but there is still distance between the implementation and operational details of clinical trials. In the meantime, China has made significant breakthroughs in drug approval. Greater than 60% of novel anticancer drugs in China received accelerated approved for their first listing. Approximately 90% of the pivotal clinical trials supporting initial drug approval used surrogate measures as end points, and one half were nonrandomized or did not have a control group. However, duplicate development without evidence of a clinical advantage compared with current therapies was widely observed. Conclusions: By presenting a multidimensional landscape of clinical trials and approvals in the real world, this review allows interested researchers, developers, and even regulators to understand what has been done and what should be done next in anticancer drug development in China. The availability of oncology therapeutic drugs in China has increased significantly since 2015, not only because of the amelioration of drug lag issues but also because of the accelerated approval of original new drugs. By using the United States as a benchmark to depict the characteristics of these original new drugs and their clinical development status, the authors report that the development of original new drugs in China shares clinical designs similar to those used in the United States; however, the Chinese designs lack international plans, and the excess of me‐too strategies needs to be further improved. [ABSTRACT FROM AUTHOR]
- Subjects :
- BIOMARKERS
DRUG approval
DRUG development
ANTINEOPLASTIC agents
GOVERNMENT agencies
Subjects
Details
- Language :
- English
- ISSN :
- 0008543X
- Volume :
- 130
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Cancer (0008543X)
- Publication Type :
- Academic Journal
- Accession number :
- 175446965
- Full Text :
- https://doi.org/10.1002/cncr.35106